Skip to main content

Table 1 Patient and tumour characteristics at time of starting trabectedin

From: Trabectedin for inoperable or recurrent soft tissue sarcoma in adult patients: a retrospective cohort study

Variable

N (%)

Age (years), median (IQR)

52 (45–61)

Gender

 Male

29 (37.7)

 Female

48 (62.3)

ECOG performance status

 0

32 (41.6)

 1

43 (55.8)

 2

2 (2.6)

Number of comorbidities

 0

33 (42.9)

 1

19 (24.7)

  ≥ 2

25 (32.4)

Prior history of cancer

 No

68 (88.3)

 Yes

9 (11.7)

Histology

 Leiomyosarcoma

32 (41.6)

 Others

21 (27.2)

 Liposarcoma

14 (18.2)

 Synovial sarcoma

10 (13)

Grade

 I

8 (10.4)

 II

16 (20.8)

 III

27 (35.1)

 Not graded/recorded

28 (36.4)

Site of primary tumour

 Thorax

6 (7.8)

 Abdomen/pelvis

11 (14.3)

 Retroperitoneum

13 (16.9)

 Uterus

21 (27.3)

 Extremity

26 (33.8)

Site of local recurrence (n = 20)

 Thorax

4 (20)

 Abdomen/pelvis

12 (50)

 Retroperitoneum

3 (15)

 Extremity

1 (5)

Site of metastasis (n = 57)

 Brain

1 (1.8)

 Lung

46 (80.7)

 Thorax

4 (7)

 Liver

15 (26.3)

 Abdomen/pelvis

13 (22.8)

 Bone

14 (24.6)

Extent of tumour

 Inoperable primary tumour

13 (16.9)

 Locally recurrent

13 (16.9)

 Recurrent metastatic tumour

44 (57.1)

 Locally recurrent and metastasis

7 (9.1)

  1. ECOG Eastern Cooperative Oncology Group